Clinical predictor of efficacy of abiraterone acetate in metastatic castraction-resistence prostate cancer progressing after doxcetaxel treatment
碩士 === 中山醫學大學 === 醫學研究所 === 104 === BACKGROUND Abiraterone acetate (AA) had been approved in the treatment of castration resistant prostate cancer (CRPC) after docetaxel. We performed a retrospective study in patients with mCRPC patients who received AA treatment after docetaxel and identify clinica...
Main Authors: | , |
---|---|
Other Authors: | |
Format: | Others |
Language: | zh-TW |
Published: |
2016
|
Online Access: | http://ndltd.ncl.edu.tw/handle/63pgug |